Format

Send to

Choose Destination
Cell Chem Biol. 2017 Sep 21;24(9):1092-1100. doi: 10.1016/j.chembiol.2017.06.012. Epub 2017 Jul 27.

Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.

Author information

1
Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands.
2
Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Noord-Holland 1066CX, the Netherlands; Foundation Hubrecht Organoid Technology (HUB), Utrecht, Utrecht 3584CM, the Netherlands; Cancer Genomics.nl, Utrecht, Utrecht 3584 CG, the Netherlands. Electronic address: e.voest@nki.nl.

Abstract

Tumor organoids are 3D cultures of cancer cells that can be derived on an individual patient basis with a high success rate. This creates opportunities to build large biobanks with relevant patient material that can be used to perform drug screens and facilitate drug development. The high take rate will also allow side-by-side comparison to evaluate the translational potential of this model system to the patient. These tumors-in-a-dish can be established for a variety of tumor types including colorectal, pancreas, stomach, prostate, and breast cancers. In this review, we highlight what is currently known about tumor organoid culture, the advantages and challenges of the model system, compare it with other pre-clinical cancer models, and evaluate its value for drug development.

KEYWORDS:

PDX; biobank; cell line; drug development; drug screen; patient-derived tumor organoids; patient-derived xenograft; three-dimensional culture; tumor organoids

PMID:
28757181
DOI:
10.1016/j.chembiol.2017.06.012
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center